Learning disabilities

The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Abnormal psychology, Autism, Psychiatric diagnosis, Psychiatry, Pervasive developmental disorders, Learning disabilities, Neurological disorders, Autism spectrum, Conditions comorbid to autism spectrum disorders, Spectrum disorder, Diagnosis of Asperger syndrome

The term "spectrum" is often associated with autism disorder as the disorder shows a wide variation in the type and severity of symptoms.

Key Points: 
  • The term "spectrum" is often associated with autism disorder as the disorder shows a wide variation in the type and severity of symptoms.
  • However, common and rare inherited genetic variations along with non-inherited traits contribute to the development of ASD.
  • According to DSM-5, patients with ASD face difficulties in social interaction, communication, activities, and nonverbal interactions; and show repetitive patterns of behaviors.
  • "Also, the growing awareness of autism spectrum disorder (ASD) has encouraged early detection and diagnosis, therefore, allowing access to services to more children as early as possible.

The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Abnormal psychology, Autism, Psychiatric diagnosis, Psychiatry, Pervasive developmental disorders, Learning disabilities, Neurological disorders, Autism spectrum, Conditions comorbid to autism spectrum disorders, Spectrum disorder, Diagnosis of Asperger syndrome

The term "spectrum" is often associated with autism disorder as the disorder shows a wide variation in the type and severity of symptoms.

Key Points: 
  • The term "spectrum" is often associated with autism disorder as the disorder shows a wide variation in the type and severity of symptoms.
  • However, common and rare inherited genetic variations along with non-inherited traits contribute to the development of ASD.
  • According to DSM-5, patients with ASD face difficulties in social interaction, communication, activities, and nonverbal interactions; and show repetitive patterns of behaviors.
  • "Also, the growing awareness of autism spectrum disorder (ASD) has encouraged early detection and diagnosis, therefore, allowing access to services to more children as early as possible.

Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Cognitive disorders, Dementia, Neuroscience, Psychiatric diagnosis, Learning disabilities, Aphasias, Frontotemporal lobar degeneration, Lewy body dementias, Lewy body, Alzheimer's disease, Neurodegeneration

b"BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT.\nA live audio webcast of the presentation can be accessed through the Events section of the Company's website at yumanity.com/events .

Key Points: 
  • b"BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT.\nA live audio webcast of the presentation can be accessed through the Events section of the Company's website at yumanity.com/events .
  • The Company\xe2\x80\x99s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\xe2\x80\x99s disease.
  • Yumanity\xe2\x80\x99s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases.
  • Yumanity\xe2\x80\x99s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig\xe2\x80\x99s disease), frontotemporal lobar dementia (FTLD), and Alzheimer\xe2\x80\x99s disease.

Global Dementia Epidemiology and Patient Flow Analysis & Forecasts 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 10, 2021
Managed care, Health, Cognitive disorders, Psychiatric diagnosis, Learning disabilities, Psychiatry, Dementia, Abnormal psychology, Cognition

b'The "Global Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Dementia Epidemiology and Patient Flow Analysis - 2021, provides Dementia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Dementia Epidemiology and Patient Flow Analysis - 2021, provides Dementia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Dementia patients, history of the disease at the population level (Dementia prevalence, Dementia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Dementia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Dementia market sizing, assessing market potential, and developing drug forecast models\nIdentify Dementia patients segments through age groups, gender, and disease sub-types\n'

2021 Global Lewy Body Dementia Epidemiology and Patient Flow Report - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Pharmaceutical, Health, Mental health, Lewy body dementia, Cognitive disorders, Psychiatric diagnosis, Branches of biology, Psychiatry, Learning disabilities, Abnormal psychology, Aging-associated diseases, Dementia, Lewy body, Lewy, Dementia with Lewy Bodies Consortium

b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Lewy Body Dementia Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Lewy Body Dementia Epidemiology and Patient Flow Analysis - 2021, provides Lewy Body Dementia epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Lewy Body Dementia patients, history of the disease at the population level (Lewy Body Dementia prevalence, Lewy Body Dementia incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nLewy Body Dementia patient flow: Lewy Body Dementia prevalence, diagnosed, and drug-treated patients\nDemographics: Lewy Body Dementia patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Lewy Body Dementia market sizing, assessing market potential, and developing drug forecast models\nIdentify Lewy Body Dementia patients segments through age groups, gender, and disease sub-types\nEvaluate Lewy Body Dementia market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210507005374/en/\n'

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results

Retrieved on: 
Wednesday, May 5, 2021
Appetite, Endocrinology, Caregiver, Psychiatric diagnosis, Abnormal psychology, Learning disabilities

\xe2\x80\x9cThe Soleno team remains committed to the development of DCCR and building an appropriate data set to support its development.

Key Points: 
  • \xe2\x80\x9cThe Soleno team remains committed to the development of DCCR and building an appropriate data set to support its development.
  • To this end, we were excited to recently present behavioral outcomes data from caregiver interviews that summarized individual patient experiences during treatment with DCCR.
  • There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder.
  • The events and circumstances reflected in the company\'s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.

Global Autism Spectrum Disorders Epidemiology and Patient Flow Report 2021: Prevalence and Incidence 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021
Health, General Health, Branches of biology, Autism, Abnormal psychology, Psychiatric diagnosis, Psychiatry, Pervasive developmental disorders, Neurological disorders, Learning disabilities, Spectrum disorder, Epidemiology of autism, Global perceptions of autism

b'The "Global Autism Spectrum Disorders Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Autism Spectrum Disorders Epidemiology and Patient Flow Analysis - 2021, provides Autism Spectrum Disorders epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Autism Spectrum Disorders Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Autism Spectrum Disorders Epidemiology and Patient Flow Analysis - 2021, provides Autism Spectrum Disorders epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Autism Spectrum Disorders patients, history of the disease at the population level (Autism Spectrum Disorders prevalence, Autism Spectrum Disorders incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nAutism Spectrum Disorders patient flow: Autism Spectrum Disorders prevalence, diagnosed, and drug-treated patients\nDemographics: Autism Spectrum Disorders patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Autism Spectrum Disorders market sizing, assessing market potential, and developing drug forecast models\nIdentify Autism Spectrum Disorders patients segments through age groups, gender, and disease sub-types\nEvaluate Autism Spectrum Disorders market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210505005453/en/\n'

Memore Launches Functional Whole Food Blends for Sustainable Cognitive Health

Retrieved on: 
Tuesday, May 4, 2021
Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Branches of biology, Psychiatry, Neuroscience, Diets, Food, Nootropic, Memory, Dementia, Alzheimer's disease

b'CHARLOTTE, N.C., May 4, 2021 /PRNewswire/ --Today, Memore [pronounced "memory"], a new direct-to-consumer brand, launches functional whole food blends that offer a convenient and versatile way to improve cognitive performance.

Key Points: 
  • b'CHARLOTTE, N.C., May 4, 2021 /PRNewswire/ --Today, Memore [pronounced "memory"], a new direct-to-consumer brand, launches functional whole food blends that offer a convenient and versatile way to improve cognitive performance.
  • Founded by husband-wife duo Brad and Erika Lepczyk, Memore carves out an important place in the consumer space for sustainable cognitive health solutions.\nEach Memore pouch contains 30 servings of brain-boosting nutrients thanks to high-quality ingredients derived from 11 whole foods and three plant-based protein sources.
  • Memore products are loaded with whole food ingredients, including brain-boosters like blueberry, spinach, sweet potato and beet.
  • To learn more, please visit www.yourmemore.com and follow @yourmemore on Instagram and Facebook .\nFounded in 2021, Memore is a company dedicated to sustainable cognitive health that offers functional blends that conveniently fill gaps in your diet with whole food nutrition shown to improve cognition, slow cognitive decline and reduce your risks of Alzheimer\'s dementia.

Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021

Retrieved on: 
Tuesday, May 4, 2021
Branches of biology, Cognitive disorders, Neurological disorders, Dementia, Neuroscience, Psychiatric diagnosis, Learning disabilities, Senescence, Frontotemporal lobar degeneration, Lewy body dementias, Neurodegeneration, Degenerative disease

b'BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at 12:00 p.m.

Key Points: 
  • b'BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that the Company will host a virtual R&D Day on Monday, May 17, 2021 at 12:00 p.m.
  • The Company\xe2\x80\x99s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson\xe2\x80\x99s disease.
  • Yumanity\xe2\x80\x99s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases.
  • Yumanity\xe2\x80\x99s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig\xe2\x80\x99s disease), frontotemporal lobar dementia (FTLD), and Alzheimer\xe2\x80\x99s disease.

Tombot, creator of the first affordable, FDA-regulated medical robotic animal, is now accepting investors

Retrieved on: 
Monday, May 3, 2021
Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Psychiatry, Branches of biology, Dementia, Neuroscience, Alzheimer's disease

Tombot conducted three rounds of consumer studies with 100s of seniors with dementia during product design.

Key Points: 
  • Tombot conducted three rounds of consumer studies with 100s of seniors with dementia during product design.
  • Tombot\'s research showed seniors strongly prefer robotic animals with realistic appearance and behaviors.\nTombot\'s Co-founder and CEO, Tom Stevens, founded the company based upon his mother Nancy Stevens\' personal battle with Alzheimer\'s dementia.
  • We\'re focusing on the needs of one patient at a time and making sure we can provide them with the necessary medical benefits.
  • You can learn more about Tombot and invest through their offering page here .\n'